Recruiting
PHASE1
Diabetes & Weight
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a…
🏢 Wave Life Sciences USA, Inc.
📅 26 Oct 2026
Find Out More →
Recruiting
PHASE2
Gut & Digestion
A Study of How the Medicine Called “Etrasimod” Works in Children With the Gut Disease Called Ulcerative Colitis
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics…
🏢 Pfizer
📅 26 Oct 2026
Find Out More →
Recruiting
PHASE3
Skin
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to
🏢 Bristol-Myers Squibb
📅 26 Oct 2026
Find Out More →
Recruiting
PHASE2
Mental Health
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
🏢 Alto Neuroscience
📅 26 Oct 2026
Find Out More →
Recruiting
PHASE2
Heart & Circulation
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on top of Standard of…
🏢 Imbria Pharmaceuticals, Inc.
📅 26 Oct 2026
Find Out More →
Recruiting
Heart & Circulation
Mechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation
The goal of this observational study is to better understand the role of measuring troponin (a protein measured by a blood test) and coronary imaging in patients presenting…
🏢 University of Edinburgh
📅 26 Oct 2026
Find Out More →
Recruiting
Diabetes & Weight
Efficacy and Safety of a Nitric Oxide Generating Dressing for Diabetic Foot Ulcers (ONWARD)
Real world evidence study on the performance and safety of a nitric oxide generating dressing on the treatment of diabetic foot ulcers
🏢 ConvaTec Inc.
📅 26 Oct 2026
Find Out More →
Recruiting
PHASE2
Cancer
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).
🏢 Sarcoma Alliance for Research through Collaboration
📅 26 Oct 2026
Find Out More →
Recruiting
PHASE3
Cancer
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon…
🏢 University of Birmingham
📅 26 Oct 2026
Find Out More →
Recruiting
PHASE3
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
To evaluate the pharmacodynamics and safety of tolvaptan in pediatric subjects with ARPKD
🏢 Otsuka Pharmaceutical Development & Commercialization, Inc.
📅 23 Oct 2026
Find Out More →
Recruiting
PHASE2
Brain & Nerves
Prevent Cognitive Decline in GBA-associated Parkinson’s Disease
This is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the…
🏢 University Hospital Tuebingen
📅 23 Oct 2026
Find Out More →
Recruiting
PHASE2
Brain & Nerves
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer’s Disease
This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is…
🏢 Sanofi
📅 23 Oct 2026
Find Out More →
Recruiting
NA
Heart & Circulation
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
The objective of this clinical investigation is to evaluate the feasibility, safety, and effectiveness of a concomitant procedure involving the Volt PFA System and Amulet 2 device in…
🏢 Abbott Medical Devices
📅 23 Oct 2026
Find Out More →
Recruiting
PHASE3
Diabetes & Weight
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.…
🏢 Merck Sharp & Dohme LLC
📅 23 Oct 2026
Find Out More →
Recruiting
PHASE1
Cancer
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic…
🏢 AstraZeneca
📅 23 Oct 2026
Find Out More →
Recruiting
PHASE3
Cancer
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvyยฎ; GS-0132; IMMU 132), versus standard of care (SOC) in participants…
🏢 Gilead Sciences
📅 22 Oct 2026
Find Out More →
Recruiting
PHASE1
Cancer
A 2-part Phase 1/2 Open-label Trial on ODM-212
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
🏢 Orion Corporation, Orion Pharma
📅 22 Oct 2026
Find Out More →
Recruiting
NA
Brain & Nerves
OPM- MEG in Non-immune And iMmune-medIated Neurological Disease
Over the past 20 years, doctors have gotten much better at spotting and treating brain conditions caused by the immune system attacking the body. These include illnesses like…
🏢 Aston University
📅 22 Oct 2026
Find Out More →